Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities

Abstract The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) ribociclib, abemaciclib, and palbociclib have transformed outcomes in patients with ER+ /HER2 − advanced breast cancer (BC). However, most patients eventually progress, and therapeutic options beyond CDK4/6i are an area of ongoing investig...

Full description

Saved in:
Bibliographic Details
Main Authors: Mashael Algethami, Ahmed Shoqafi, Ayat Lashen, Shatha Alqahtani, Jake Spicer, Ahmad ALtayyar, Çağla Tosun, Jennie N Jeyapalan, Nigel P. Mongan, Victoria James, Emad A. Rakha, Srinivasan Madhusudan
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
CDK4
CDK6
Palbociclib
Ribociclib
Abemaciclib
Mechanism of resistance
Online Access:https://doi.org/10.1038/s41598-025-11052-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-11052-4

Similar Items